Becton Dickinson has seen significant changes in share ownership recently; while corporations such as Ascent Group, WBI Investments, and Goldman Sachs Groups have purchased shares, entities like Generation Investment Management and Rafferty Asset Management sold their stakes. Acclaimed executive Claire Fraser has sold 917 shares. On the brighter side, BD's Board declared dividends and additionally authorized 10 million more share repurchases. Notably, BD has concluded a $750 million repurchase in FY25. The company has been under radar for its Q3 earnings beat and raised guidance, instigating several firms like Piper Sandler and Stifel to increase their stock price target for Becton Dickinson. Despite a stronger forecast and outperforming Q3 earnings, the recent revelation of underperforming in the Healthcare sector and a 28% loss endured by long-time shareholders of BDX generates concerns. Amid this, there are continual assessments of the company's valuation. In terms of business progress, BD is gearing forward by investing $35 million in its Nebraska Facility and expanding its prefab flush syringe manufacturing. The company is also making strategic moves with its recent venture with Waters Corp to build a high-volume diagnostic leader. BDX's regulatory and product advancement prospects look promising with the FDA clearance for a point-of-care COVID-19 test.
Becton Dickinson and BDX News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Sat, 13 Sep 2025 18:57:08 GMT -
Rating 6
- Innovation 3
- Information 9
- Rumor -2
